Xenobiotica 2012-02-01

A high throughput in vitro mrp2 assay to predict in vivo biliary excretion.

Federico Colombo, Catherine Armstrong, Jianmin Duan, Nathalie Rioux

Index: Xenobiotica 42 , 157-163, (2012)

Full Text: HTML

Abstract

Prediction of biliary excretion is a challenge for drug discovery scientists due to the lack of in vitro assays. This study explores the possibility of establishing a simple assay to predict in vivo biliary excretion via the mrp2 transport system. In vitro mrp2 activity was determined by measuring the ATP-dependent uptake of 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) in canalicular plasma membrane vesicles (cLPM) from rat livers. The CDCF uptake was time- and concentration-dependent (K(m) of 2.2 ± 0.3 µM and V(max) of 115 ± 26 pmol/mg/min) and strongly inhibited by the mrp2 inhibitors, benzbromarone, MK-571, and cyclosporine A, with IC(50) values ≤ 1.1 µM. Low inhibition of CDCF uptake by taurocholate (BSEP inhibitor; 57 µM) and digoxin (P-gp inhibitor; 101 µM) demonstrated assay specificity towards mrp2. A highly significant correlation (r(2) = 0.959) between the in vitro IC(50) values from the described mrp2 assay and in vivo biliary excretion in rats was observed using 10 literature compounds. This study demonstrated, for the first time, that a high throughput assay could be established with the capability of predicting biliary excretion in the rat using CDCF as a substrate.


Related Compounds

Related Articles:

Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.

2011-02-01

[Nephrology (Carlton.) 16(2) , 156-62, (2011)]

The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense.

2015-04-02

[Oncogene 34(14) , 1799-810, (2015)]

[Clinical strategies for prevention of drug-induced urinary calculi].

2011-10-01

[Clin. Calcium 21(10) , 1457-63, (2011)]

Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment.

2015-01-01

[Biol. Pharm. Bull. 38(3) , 487-92, (2015)]

Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.

2014-01-01

[Biol. Pharm. Bull. 37(12) , 1866-71, (2014)]

More Articles...